Company Description
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications.
The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare.
The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States.
MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 895 |
| CEO | Joseph H. Capper |
Contact Details
Address: 1775 W Oak Commons Court, Ne Marietta, Georgia 30062 United States | |
| Phone | (770) 651-9100 |
| Website | mimedx.com |
Stock Details
| Ticker Symbol | MDXG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001376339 |
| CUSIP Number | 602496101 |
| ISIN Number | US6024961012 |
| Employer ID | 26-2792552 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| William F. Hulse IV | General Counsel and Chief Administrative Officer |
| Dr. Robert Benjamin Stein M.D., Ph.D. | President of Regenerative Medicine and Biologics Innovation |
| Joseph H. Capper | Chief Executive Officer and Director |
| Douglas C. Rice CPA | Chief Financial Officer |
| Scott M. Turner | Senior Vice President of Operations and Procurement |
| Matthew M. Notarianni | Head of Investor Relations |
| Mark P. Graves | Senior Vice President and Chief Compliance Officer |
| Hilary Dixon | Vice President of Investor Relations and Corporate Strategic Communications |
| Kate Surdez | Chief Human Resources Officer |
| Dr. David H. Mason Jr. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 20, 2024 | 144 | Filing |
| Feb 16, 2024 | 144 | Filing |
| Feb 15, 2024 | 144 | Filing |
| Feb 14, 2024 | 144 | Filing |